Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with advanced hematologic malignancies

Trial Profile

Phase 1 study of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with advanced hematologic malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Cytarabine/daunorubicin (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 19 Dec 2018 Results of the population pharmacokinetics analysis based on pooled data from Study 101, 206 and 301 (n=195) published in the Journal of Clinical Pharmacology
    • 08 Jun 2009 Final data were presented on the activity of CPX-351 against leukemia at the European Hematology Association (EHA) congress, Berling, Germany, according to Celator Pharmaceuticals media release.
    • 09 Dec 2008 Final results were presented at the 50th American Society of Hematology (ASH) Annual Meeting, according to a Celator Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top